Scientific Rationale for Combination Therapy in Patients with GIST and PEAK Phase 3 Data

Dr. Heinrich explains the scientific foundation for combining bezuclastinib with sunitinib, addressing the fundamental problem of polyclonal resistance emerging after imatinib progression. Secondary KIT resistance involves heterogeneous mutations spanning both ATP-binding pocket (exons 13/14) and activation loop (exons 17/18) regions.

The sequential approach resembles "whack-a-mole" where treating one resistance mechanism allows alternative pathways to emerge and dominate. Historical attempts to develop single agents covering both resistance patterns proved challenging, leading to the alternative strategy of combining 2 drugs with complementary coverage.

Sunitinib effectively targets ATP-binding pocket mutations, while bezuclastinib represents a highly selective type I KIT inhibitor with potent activity against activation-loop mutations. The combination approach allows each agent to address half the resistance problem rather than requiring one drug to solve everything.

Early phase 1b/2a combination data showed encouraging median progression-free survival of 12.1 months with 80% clinical benefit rate in heavily pretreated populations, providing proof-of-concept for the combination strategy.

The PEAK Phase 3 primary results presented at ASCO 2026 demonstrated that the combination met its primary endpoint with statistically significant improvement in median progression-free survival: 16.5 versus 9.2 months (HR 0.50, 95% CI 0.39-0.65, P < 0.0001), representing a 50% reduction in progression or death risk. Objective response rates nearly doubled from 26% to 46% with the combination. The sunitinib monotherapy arm achieved the longest progression-free survival ever reported for the agent, yet the combination still demonstrated substantial superiority. Safety findings showed manageable profiles with no new safety signals identified. The study utilized blinded independent central review for progression assessment, providing high-quality, stringent data free from investigator bias.